145 related articles for article (PubMed ID: 30474875)
1. Severe vemurafenib-induced photosensitivity in a 6-year-old boy.
Jew OS; Provini LE; Treat JR
Pediatr Dermatol; 2019 Jan; 36(1):e62-e63. PubMed ID: 30474875
[TBL] [Abstract][Full Text] [Related]
2. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
3. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
5. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
6. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
Chen P; Chen F; Zhou B
Clin Exp Dermatol; 2019 Apr; 44(3):243-251. PubMed ID: 30280426
[TBL] [Abstract][Full Text] [Related]
11. [Drug-induced photosensitivity].
Marguery MC
Rev Prat; 2000 Jun; 50(12):1315-9. PubMed ID: 10972072
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
13. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
14. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
15. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
17. [Drug-induced cutaneous photosensitivity. Results of a consensus meeting].
Roujeau JC; Beani JC; Dubertret L; Guillaume JC; Jeanmougin M; Danan G; Lagier G; Benichou C
Therapie; 1989; 44(3):223-7. PubMed ID: 2528839
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib-related photosensitivity.
Eberlein B; Biedermann T; Hein R; Posch C
J Dtsch Dermatol Ges; 2020 Oct; 18(10):1079-1083. PubMed ID: 32558291
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
